27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Hippocampal volume was the primary determinant of memory decline, whereas executive function (EXEC) decline was related to multiple brain components. 5 key findings →
Design: longitudinal study Participants: 103 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Evidence suggests that a high concentration of C-reactive protein (CRP) is a cardiovascular risk factor and an important correlate of cognitive disorders and depression. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
When proper normative values are used, only age and education, and not race or ethnicity, are associated with higher frequency of MCI. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Only behavior management therapies, specific types of caregiver and residential care staff education, and possibly cognitive stimulation appear to have lasting effectiveness for the management of dementia-associated neuropsychiatric symptoms. 2 key findings →
Participants: 1,632 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Psychotic symptoms are common and persistent in patients with Alzheimer's disease. 5 key findings →
Design: longitudinal study Participants: 9,749 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Future confirmation in a larger study is needed to fully demonstrate rosiglitazone's therapeutic potential. 3 key findings →
Participants: 20 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The majority of dementia-related deaths in the United States occurred in nursing homes (66.9%). 5 key findings →
Design: cross-sectional Participants: 88,523 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This multicenter trial showed no benefit of divalproex sodium for treatment for agitation in dementia at a mean dose of 800 mg/day over 6 weeks. 3 key findings →
Participants: 75 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The dementia with Lewy bodies (DLB) Consortium has revised criteria for the clinical and pathologic diagnosis of DLB incorporating new information about the core clinical features and suggesting improved methods to assess them. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The AD8 is a brief, sensitive measure that reliably differentiates between nondemented and demented individuals. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Vascular and inflammatory factors may play an important role in the pathogenesis of dementia. 4 key findings →
Participants: 2,835 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There is evidence from a population-based study of an inverse relationship between monounsaturated fatty acids (MUFA) energy intake and age-related cognitive decline (ARCD), while high polyunsaturated fatty acids (PUFA) intake was positively associated with cognitive impairment in elderly subjects. 2 key findings →
Design: longitudinal study Participants: 704 Evidence: high
Full summary, score breakdown and related studies → Original source
Whilst palliative care is appropriate for elderly patients with chronic, non-malignant disease, few of these patients access such care compared with cancer patients. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Despite the increased interest in palliative care for patients with dementia there is currently little evidence on which to base such an approach. 1 key finding →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The direct visualization of retinal vessels provides a unique opportunity to study cerebral small vessel disease, because these vessels share many features. 2 key findings →
Design: cohort study Participants: 490 Evidence: moderate
Full summary, score breakdown and related studies → Original source
For the cohort of patients that remained on therapy > or =60 days, the mean time to treatment discontinuation was 331 days (95% confidence interval [CI], 307-355) for rivastigmine patients (n = 392) versus 337 days (95% CI, 322-352) for donepezil patients (n = 1288). 4 key findings →
Design: cohort study Participants: 392 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Capturing the dynamics of gray matter (GM) atrophy in relation to the conversion from mild cognitive impairment (MCI) to clinically probable Alzheimer's disease (AD) would be of considerable interest. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We examined whether cognitive function at baseline affected cognitive and cardiovascular outcomes in the Study on COgnition and Prognosis in the Elderly (SCOPE), a blood pressure (BP)-lowering intervention trial. 4 key findings →
Design: open-label trial Participants: 2,070 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These data suggest that AD pathology is more likely to be clinically expressed as dementia in women than in men. 5 key findings →
Design: cohort study Participants: 57 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Idiopathic Parkinson's disease (PD) is a neurodegenerative disorder associated with akinesia, tremor and rigidity. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Unsaturated fatty acids are important constituents of neuronal cell membranes and have neuroprotective, antioxidant, and anti-inflammatory properties. 4 key findings →
Design: cohort study Participants: 5,289 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Subclinical structural brain abnormalities in high-functioning older adults can increase the risk of developing physical disabilities and declining in motor performance. 1 key finding →
Design: longitudinal study Participants: 2,450 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this cohort study, statin therapy was not associated with a decreased risk of dementia. 5 key findings →
Design: cohort study Participants: 2,798 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Stress was more often reported by care providers who had been working for 1 to 2 years (compared with longer); in addition, those who had been working for 1 to 2 years were more likely to espouse hopeful or person-centered attitudes than those who had been working for a longer period of time. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →